JPMorgan Chase Bank, N.A. v. Synergy Pharmacy Services, Inc.

CourtDistrict Court, M.D. Florida
DecidedJune 9, 2021
Docket8:18-cv-01253
StatusUnknown

This text of JPMorgan Chase Bank, N.A. v. Synergy Pharmacy Services, Inc. (JPMorgan Chase Bank, N.A. v. Synergy Pharmacy Services, Inc.) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
JPMorgan Chase Bank, N.A. v. Synergy Pharmacy Services, Inc., (M.D. Fla. 2021).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA TAMPA DIVISION

JPMORGAN CHASE BANK, N.A.,

Plaintiff,

v. Case No. 8:18-cv-1253-VMC-SPF SYNERGY PHARMACY SERVICES, INC., PETER BOLOS, ANDREW WILLIAM ASSAD, MICHAEL PALSO, and SYNERGY PHARMACEUTICALS, LLC,

Defendants. ______________________________/ ORDER This matter comes before the Court upon consideration of Plaintiff JPMorgan Chase Bank, N.A.’s Renewed Motion for Summary Judgment (Doc. # 113), filed on March 12, 2021. Defendants Michael Palso, Synergy Pharmacy Services, Inc. (“Synergy Pharmacy”), and Synergy Pharmaceuticals, LLC (“Synergy Pharmaceuticals”), failed to respond. Defendant Andrew William Assad responded on April 9, 2021. (Doc. # 119). Defendant Peter Bolos responded on April 30, 2021. (Doc. # 125). Chase has replied. (Doc. ## 122, 130). For the reasons that follow, the Motion is granted. I. Background On November 13, 2014, Synergy Pharmacy executed and delivered to Chase a promissory note in the original principal amount of $750,000.00. Synergy Pharmacy executed a credit agreement contemporaneously with the note. (Doc. # 113-1 at 3, Ex. A). Paragraph 8.16 of the credit agreement provides in relevant part that “each Obligor waives (a) any right to receive notice of the following matters before the Bank enforces any of its rights: (i) any demand, diligence, presentment, dishonor and protest or (ii) any action that the Bank takes regarding any Person, any Collateral, or any of the Liabilities, that it might be entitled to by law or under

any other agreement.” (Id.). On November 13, 2014, contemporaneous with the note and credit agreement, Bolos, Assad, and Synergy Pharmaceuticals each executed and delivered to Chase a continuing guaranty (the “Bolos Guaranty”, the “Assad Guaranty” and the “Synergy Pharmaceuticals Guaranty,” respectively). (Id. at 3, Exs. C, D, E). Pursuant to the Bolos Guaranty, Assad Guaranty, and Synergy Pharmaceuticals Guaranty, Bolos, Assad and Synergy Pharmaceuticals, jointly and severally, guaranteed Synergy Pharmacy’s obligations under the note and related (including future) loan documents. (Id.). The Bolos, Assad, and Synergy Pharmaceuticals Guaranties provided that no notice of default

was required in the “Remedies/Acceleration” section of each guaranty: All obligations of the Guarantor to the Bank under this Guaranty, whether or not then due or absolute or contingent, shall, at the option of the Bank, without notice or demand, become due and payable immediately upon the occurrence of any default or event of default under the terms of any of the Liabilities or otherwise with respect to any agreement related to the Liabilities (or any other event that results in acceleration of the maturity of any Liabilities, including without limitation, demand for payment of any Liabilities constituting demand obligations or automatic acceleration in a legal proceeding) or the occurrence of any default under this Guaranty. (Id. at Exs. C, D, E)(emphasis added). On May 31, 2016, Chase agreed to renew the note, and “Synergy Pharmacy executed a Line of Credit Note in the amount of $2,000,000.00” (“renewal note”; the note and renewal note hereinafter collectively referred to as “the loan”). (Id. at 3, Ex. B). Along with the renewal note, Synergy Pharmacy executed an additional Credit Agreement, which also contained a waiver of notice in Paragraph 8.16. (Id.). On May 31, 2016, contemporaneous with the renewal note and the additional Credit Agreement, Palso executed and delivered to Chase a Continuing Guaranty (the “Palso Guaranty”). (Id. at 3, Ex. F). Pursuant to the Palso Guaranty, Palso along with Bolos, Assad, and Synergy Pharmaceuticals, jointly and severally, guaranteed Synergy Pharmacy’s obligations under the loan and related loan documents. (Id.). The Palso Guaranty, like the Assad, Bolos, and Synergy Pharmaceuticals Guaranties, did not require a notice of default, as specified in the “Remedies/Acceleration” section. (Id.). According to the affidavit of Barbra Lopez, Chase’s Special Credits Analyst II, Synergy Pharmacy “failed to pay under the terms of the Contract and is in default.” (Id. at 3, Ex. G). On or about March 5, 2018, Chase sent demand letters to

Synergy Pharmacy, Bolos, Assad, Palso and Synergy Pharmaceuticals, LLC. (Id. at 4, Ex. H). The demand letters stated that Synergy Pharmacy was in default because it did “not provid[e] required financials within a timely manner.” (Id. at Ex. H). Although Chase maintains in its Motion that Defendants failed to “provide required financials in a timely manner” (Doc. # 113 at 4), Chase does not provide any record evidence identifying the financial records in question or establishing that such financial records were not turned over besides the demand letters. According to Bolos’ declaration, Bolos, Synergy Pharmacy Services, and Synergy Pharmaceuticals “periodically provided

Chase with financial reporting during the term of the Synergy Loan.” (Doc. # 125 at 14). Additionally, Bolos stated in his declaration that “[a]s of March 5, 2018, the date of the letters declaring the Synergy Loan in default, the Synergy Loan was current with respect to payments.” (Id.). Nevertheless, Lopez averred in her affidavit that “no payments have been made on the Contract since September 28, 2018.” (Doc. # 113-1 at 4). Indeed, the Account Transaction History reflects that, although the loan matured on June 1, 2018, no payments were successfully made between March 2, 2018, and when Chase charged off the loan on June 27, 2018.

(Id. at Exs. B & G). And the subsequent records from the separate account system Chase maintains for servicing “certain severely delinquent loans” reflects that no payments at all have been made since September 28, 2018, and the balance is outstanding. (Id. at 4, Ex. I). According to Lopez’s affidavit, as of March 3, 2021, Synergy Pharmacy owes Chase the following amounts under the loan: Unpaid principal balance: $1,787,692.81 Accrued interest 45,079.79 Late fees and costs 775.00 TOTAL $1,833,547.60 (Id. at 4, Exs. G, I). Regarding the interest calculation, Bolos declared that “[i]t is unclear to [him] how Chase calculated interest of $45,079.79.” (Doc. # 125 at 14). Chase owns and holds the loan. (Doc. # 113-1 at 3, Exs. A, B). Chase initiated this action against Defendants on May 24, 2018. (Doc. # 1). It filed its amended complaint on August 27, 2018, asserting claims for breach of note against Synergy Pharmacy (Count I), breach of guaranty against Bolos (Count

II), breach of guaranty against Assad (Count III), breach of guaranty against Palso (Count IV), breach of guaranty against Synergy Pharmaceuticals (Count V), and foreclosure of personal property against Synergy Pharmaceuticals (Count VI). (Doc. # 32). On October 10, 2019, the Court dismissed Count VI without prejudice at the parties’ request, leaving only Counts I through V. (Doc. # 55). Synergy Pharmacy, Synergy Pharmaceuticals, Bolos, and Palso filed their answer and affirmative defenses on September 10, 2018. (Doc. # 33). Assad then filed his answer and affirmative defenses on November 5, 2019. (Doc. # 57). Discovery has closed and Chase now seeks summary

judgment on Counts I through V. (Doc. # 113). Only Assad and Bolos have responded. (Doc. ## 119, 125). Chase has replied. (Doc. ## 122, 130). The Motion is now ripe for review. II. Legal Standard Summary judgment is appropriate “if the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a). A factual dispute alone is not enough to defeat a properly pled motion for summary judgment; only the existence of a genuine issue of material fact will preclude

a grant of summary judgment. Anderson v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Jeffery v. Sarasota White Sox, Inc.
64 F.3d 590 (Eleventh Circuit, 1995)
Mize v. Jefferson City Board of Education
93 F.3d 739 (Eleventh Circuit, 1996)
Allen v. Tyson Foods, Inc.
121 F.3d 642 (Eleventh Circuit, 1997)
Burger King Corp. v. Weaver
169 F.3d 1310 (Eleventh Circuit, 1999)
Shotz v. City of Plantation, FL
344 F.3d 1161 (Eleventh Circuit, 2003)
Hickson Corp. v. Northern Crossarm Co.
357 F.3d 1256 (Eleventh Circuit, 2004)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Marvin Morris v. Harold Ross
663 F.2d 1032 (Eleventh Circuit, 1981)
Cox v. CSX Intermodal, Inc.
732 So. 2d 1092 (District Court of Appeal of Florida, 1999)
Abbott Labs., Inc. v. General Elec. Capital
765 So. 2d 737 (District Court of Appeal of Florida, 2000)
National Loan Investors v. Joymar Assoc.
767 So. 2d 549 (District Court of Appeal of Florida, 2000)
White Construction Co. v. Martin Marietta Materials, Inc.
633 F. Supp. 2d 1302 (M.D. Florida, 2009)
Perry v. Fairbanks Capital Corp.
888 So. 2d 725 (District Court of Appeal of Florida, 2004)
Herbert v. Architect of the Capitol
839 F. Supp. 2d 284 (District of Columbia, 2012)
Samples v. City of Atlanta
846 F.2d 1328 (Eleventh Circuit, 1988)

Cite This Page — Counsel Stack

Bluebook (online)
JPMorgan Chase Bank, N.A. v. Synergy Pharmacy Services, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/jpmorgan-chase-bank-na-v-synergy-pharmacy-services-inc-flmd-2021.